Also known as: Securities and Exchange Commission, Securities & Exchange Commission
XRP hovered near $1.09 on July 25 despite Ripple's EU MiCA approval and Evernorth's $1 billion XRP treasury plan. Technical resistance and slowing ETF inflows capped gains; RLUSD supply reached $1.51B.
Institutional investors disclosed mixed moves in AstraZeneca plc during recent quarters, with several large funds selling while others initiated new positions. The company beat earnings expectations with $2.58 EPS and $15.29 billion in revenue. Analysts maintain a 'Moderate Buy' consensus with a $211.00 average price target.
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
The SEC is pursuing insider trading cases involving inadvertent tips of MNPI, including a cousin who traded on confidential FDA approval news and a family member with workspace access during an acquisition.
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
Vanguard increased its Moderna stake by 1.0% in the fourth quarter to 41.6 million shares worth $1.23 billion. Other institutional investors also adjusted positions, while 75.33% of the stock is held by institutions and hedge funds.
Moderna reported Q4 revenues of $678 million, down 29.8% year-over-year but beating analyst expectations. The FDA reversed course and will review the company's mRNA flu vaccine application.
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
Brainstorm Cell Therapeutics announced a $1 million private placement at a premium to market price to support its upcoming Phase IIIb trial of NurOwn stem cell therapy for amyotrophic lateral sclerosis.
Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers after the companies reached an agreement to sell branded Wegovy and Ozempic through the Hims platform. The settlement ends a dispute that began when Hims planned to offer a cheaper off-brand version of Wegovy.
